FDA's Updated Criteria for Breakthrough Device Designation

Apr 3, 2026, 2:28 AM

Hover over text to view sources

The US Food and Drug Administration (FDA) has been revising its framework for what constitutes a 'breakthrough' medical device, aiming to expedite access to innovative technologies that can significantly improve patient outcomes. The Breakthrough Devices Program (BDP), initiated under the 21st Century Cures Act of 2016, allows certain medical devices that meet specific criteria to receive prioritized review, potentially leading to faster market authorization.

Under the revised guidelines released on September 15, 2023, the FDA is now considering a medical device's potential to address health and healthcare disparities as part of its evaluation criteria. This marks a significant shift in the FDA's perspective, highlighting the agency's commitment to improving access to effective healthcare solutions for diverse populations.

To qualify for breakthrough designation, a device must provide more effective treatment or diagnosis for life-threatening or severely debilitating conditions and meet at least one of four secondary criteria. These include representing breakthrough technology, offering significant advantages over existing treatments, addressing an unmet medical need, or being in the best interest of patients.

The BDP aims to facilitate quicker development and review processes while maintaining rigorous standards for safety and effectiveness. However, as of June 30, 2023, only about 9.6% of devices designated as breakthrough have received marketing authorization, indicating challenges in meeting the necessary evidence requirements.

Emphasis on Health Equity

The FDA's recent updates place greater importance on how devices can improve health equity. For example, the agency may consider whether a device's design enhances accessibility for disadvantaged populations, thereby increasing its potential to deliver effective treatments. This evolution in criteria reflects a broader understanding of how social determinants of health can impact treatment outcomes and patient access to care.

One recent example of a medical device that exemplifies this shift is the EvoLiver test, which received breakthrough designation for its ability to detect hepatocellular carcinoma in high-risk cirrhosis patients. The test boasts a significantly higher sensitivity compared to traditional methods, potentially transforming liver cancer surveillance and improving access to timely treatment.

Regulatory Challenges and Opportunities

While the BDP aims to accelerate innovation, it is not without challenges. The FDA's recent guidance underscores the need for manufacturers to showcase how their devices address disparities and improve outcomes for specific populations. This focus on health equity may necessitate changes in clinical trial designs to ensure diverse representation of patients.

Moreover, the Centers for Medicare & Medicaid Services (CMS) has proposed repealing the Medicare Coverage of Innovative Technology and Definition of "Reasonable and Necessary" rule, which previously aimed to provide expedited coverage for breakthrough devices. The CMS argues that the FDA's safety and effectiveness standards alone are insufficient for guaranteeing Medicare coverage, highlighting the need for robust clinical data relevant to the Medicare population.

This potential repeal raises concerns about the accessibility of breakthrough devices for Medicare beneficiaries, as it may slow the introduction of innovative technologies into the healthcare system. The CMS has stated that while the MCIT/R&N rule was intended to enhance access, it could lead to coverage decisions without adequate evidence of a product's necessity for specific patient populations.

Conclusion

The FDA's evolving view on what defines a breakthrough device reflects a growing recognition of the complexities surrounding healthcare access and equity. By emphasizing the importance of addressing health disparities, the agency is paving the way for a more inclusive approach to medical device innovation. As these changes unfold, it will be crucial for manufacturers to adapt to the new criteria and ensure that their products meet both regulatory and patient needs in a rapidly evolving healthcare landscape.

The impact of these changes will likely continue to shape the future of medical device development and access, affecting stakeholders from manufacturers to healthcare providers and patients alike. As the FDA and CMS navigate these regulatory waters, the goal remains clear: to enhance patient care through timely access to life-saving technologies while ensuring that all populations benefit equally from advancements in medical science.

Rocket Pharmaceuticals Secures FDA Approval for Kresladi Therapy

Rocket Pharmaceuticals has received accelerated FDA approval for Kresladi, a gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder affecting children's immune systems. This milestone not only offers hope for affected families but also positions Rocket for future growth as it prepares to conduct necessary post-marketing trials.

Regeneron Science Talent Search 2026 Awards Over $1.8 Million to Young Innovators

The 2026 Regeneron Science Talent Search honored top high school scientists, awarding more than $1.8 million in prizes. Connor Hill won the top award for his innovative work in computational mathematics, while other finalists explored fields such as neural science and cancer treatment.

UVA Health Joins Global Effort to Innovate Pediatric Cancer Treatments

UVA Health researchers have partnered with an international consortium to develop advanced treatments for childhood cancers. This collaboration aims to address the lack of investment in pediatric drug development and improve outcomes for patients facing aggressive forms of cancer.

AI-Enhanced Mammograms: A New Frontier in Women's Heart Health

Recent studies indicate that artificial intelligence (AI) can analyze mammograms to assess heart disease risk in women, potentially transforming routine breast screenings into dual-purpose health checks. This innovative approach aims to better identify cardiovascular risks, particularly in women often overlooked in traditional screenings.

Study Reveals ChatGPT Health 'Under-Triaged' Medical Emergencies

A recent study published in Nature Medicine has revealed that ChatGPT Health, OpenAI's specialized medical chatbot, under-triaged over half of medical emergencies. The research highlights significant flaws in the AI's ability to assess urgent medical situations, potentially putting users at risk.